Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010827 | 0.77 | SLC6A3 (0.42) | CHRM2CHRM4CHRM3SLC6A4SLC6A3 | |
| SCHEMBL17199517 | 0.75 | CYP1A2 (0.46) | CYP1A2HIF1ACHRM2CHRM4CHRM3 | |
| SCHEMBL7948341 | 0.74 | SLC6A3 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7955928 | 0.74 | SLC6A3 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1333467 | 0.74 | CYP2D6 (0.35) | CYP1A2HIF1AKMT2A | |
| SCHEMBL9729217 | 0.73 | CYP1A2 (0.52) | CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL11359745 | 0.73 | CYP1A2 (0.52) | CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL11359734 | 0.73 | CYP1A2 (0.52) | CYP1A2HIF1AALDH1A1KMT2A | |
| SCHEMBL916946 | 0.73 | ALDH1A1 (0.44) | CYP1A2CHRM2CHRM4CHRM3ALDH1A1 | |
| SCHEMBL1011715 | 0.72 | CYP1A2 (0.89) | CYP1A2HIF1ASLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| US-6486323-B1 | Process for producing optically active tropinonemonocarboxylic acid derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | CYP1A2 51/4885HIF1A 3530/4885CHRM2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.